Primary intracranial leiomyoma is a rare tumour of mesenchymal origin, with less than 30 cases reported in literature including two cases from the Indian subcontinent. In this article, we describe a case of primary intracranial leiomyoma in an immunocompromised patient with a brief review of literature.
Introduction
Leiomyomas are benign tumours of mesenchymal origin (ideally non-metastasising) predominantly seen in the genitourinary system. However, metastasis to distant organs like spinal cord, breast, pleura, brain, rib and vertebrae, appendix, parametrium, heart, vessels, bone, muscle, soft tissue, lymph node, and retroperitoneum have been reported. [1] Our search of literature revealed around 30 reported cases of primary intracranial leiomyoma. In this article, we describe a case of primary intracranial leiomyoma in an immunocompromised adult with a brief review of available literature.
Case History
A 46-year old male presented with the chief complaint of giddiness for an hour associated with an episode of aphasia following which he had difficulty in speaking. He complained of intermittent headaches for the past 6 years. The headache began as shooting type, then progressed to dull type, localised to left temporal region. There were no exaggerating or relieving factors, no history of trauma, no bowel and bladder disturbances.
He was a known case of HIV and Hepatitis B virus infection on antiretroviral therapy.
On Examination, the patient was afebrile with normal vital signs. Examination of the central nervous system was unremarkable.
Investigations revealed that the patient had mild leukopenia 3.9 × 10 6 cells/µL, ESR-47 mm/hr, He was seropositive for both HIV and Hepatitis B surface antigen (HBsAg). This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. 
Discussion
Leiomyoma is a type of smooth muscle tumour considered to be a benign entity although may occasionally metastasise resulting in lesions in distal sites like the brain. Intracranial leiomyomas are rare, with the primary variety being even rarer. The first report of primary intracranial leiomyoma was done by kroe et al. in 1968. They suggested that the origin of the tumour to be the vascular smooth muscle [2] of the brain. Several cases were reported after kroe et al. -Most of which were in immunocompromised patients. There is a significant rise in these immunosuppression related smooth muscle tumours in the recent decade due to the advances in antiretroviral therapy and increase in number of organ transplants and associated immunosuppressive therapies. These smooth muscle tumours may be either benign -leiomyomas or malignant -leiomyosarcoma.
Our search of literature revealed about 30 cases [3, 4] of primary intracranial leiomyoma [ Tables 1 and 2 ] reported, of which only 2 cases have been reported from India. The peak age of incidence was between 25-50 years with the youngest and oldest patients of age 4 and 68 years respectively. There was a slight female preponderance with 17 of the 30 cases being females.
Site: The commonest reported site of occurrence was the middle cranial fossa/temporal lobe followed by the sellar/ parasellar/cavernous region. Other reported sites include basal ganglia, frontal region and intraventricular in the lateral ventricle.
Size: The tumours were usually small at presentation with the mean size around 2-4 cm. The largest on record measured 8 cm.
Immune status: Intracranial leiomyomas are commonly associated with immunocompromised states, however seven of the reported cases were in patients with no known immunodeficiency. Of the remaining cases 11 were positive for HIV, four were post-transplant recipients and immune status was unavailable in eight of the patients.
Epstein-Barr virus (EBV) has been implicated in many of these smooth muscle tumours particularly in association with HIV infection. EBV positivity was noted in 12 cases. Data on EBV status was unavailable in these 12 cases. Eight cases were both HIV and EBV positive. Extensive literature is available on the smooth muscle tumours in immunocompromised patients particularly in association with HIV and EBV infections. However, whether the association is significant or just a confounding finding given the immunocompromised state of several of these patients remains unknown. Our patient was positive for both HIV and HBsAg.
Imaging features: Imaging feature of primary intracranial leiomyoma closely resembles that of meningioma with hemangiopericytoma, schwannoma, solitary fibrous tumour as the differentials. The imaging features may resemble lymphoma in the setting of immunosuppression. Other differentials to be considered include glioblastoma multiforme, intracranial angioleiomyoma, meningeal sarcoma and metastasis.
Most tumours appeared as hyper dense solid extra axial masses with perifocal oedema with only one case presenting as a complex cyst. Calcification was reported in four cases, bone erosion/invasion was reported in two cases and invasion of the superior sagittal sinus in one case. Invasion into the adjacent pituitary was noted in two cases. Multifocality was noted in two of the cases, but were still included under primary intracranial leiomyomas because of low MIB (proliferation index). Limited literature is available on the MR imaging of these tumours. T1 hypointensity and T2 hyperintensity was seen with homogeneous enhancement post contrast. However, absence of diffusion is a feature that differentiates it from tumours like lymphoma. Therefore in an immunocompromised patient with an intracranial extra axial lesion, leiomyoma should be considered in addition to the usual differentials.
[5]
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